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malarial disease. We tested this hypothesis using a murine co-infection model of 27 schistosomiasis and cerebral malaria. C57BL/6 mice were infected with Schistosoma 28 mansoni and 8 to 9 weeks later, when Schistosoma infection was patent, mice were 29 co-infected with Plasmodium berghei ANKA strain. We found that a concomitant 30
Schistosoma infection increased parasitemia at the beginning of the P. berghei 31 infection. It did not protect against P. berghei-induced weight loss and hypothermia, 32
and P. berghei-mono-infected as well as S. mansoni-P. berghei-co-infected animals 33
showed a high case fatality between days 6 and 8 of malarial infection. However, co-34 infection significantly reduced P. berghei-induced brain pathology. Over 40% of the 35
S. mansoni-P. berghei-co-infected animals that died during this period were 36
completely protected against haemorrhaging, plugging of blood vessels and 37 infiltration, indicating that mortality in these animals was not related to cerebral 38 disease. Schistosoma mansoni-P. berghei-co-infected mice had elevated plasma 39 concentrations of IL-5 and IL-13 and on day 6 lower levels of IFN-, IL-10, monocyte 40 chemoattractant protein-1 (MCP-1) and monokine induced by IFN-(MIG) than 41 to the immune system, they are able to avoid immune destruction and can persist in 76 their host for decades (Chabasse et al., 1985) . Their long-term survival is facilitated 77 by immuno-regulatory mechanisms specific for the different parasitic life cycle 78 stages. For example, schistosomal parasites in the egg-laying phase (patent 79 infection) modulate dendritic cells and macrophages and induce regulatory T cells 80 (reviewed in Dunne and Cooke (2005) ). This generates Th2 and anti-inflammatory 81 cytokine responses. Thus, a regulatory network evolves which protects the parasites 82 from elimination, but also prevents severe inflammation and resulting 83 immunopathology. 84
Immune responses in chronic helminth infections can dampen the immune 85 response to third party antigens (Maizels and Yazdanbakhsh, 2003) . It has been 86
proposed that anti-inflammatory and Th2 responses to patent schistosomiasis might 87 inhibit parasite control of early stage malaria, but down-modulate the malaria-induced 88 pro-inflammatory response and limit severe pathology at later stages of malaria 89 (Hartgers and Yazdanbakhsh, 2006 ). The present study investigates this hypothesis 90 using a co-infection model of schistosomiasis (Schistosoma mansoni) and CM 91 (Plasmodium berghei ANKA strain) in C57BL/6 mice. These mice were selected as 92 they develop cerebral malaria at a high rate, probably due to their pro-inflammatory / 93
Th1 predisposition (Lou et al., 2001) . To investigate the impact of patent 94 schistosomiasis on P. berghei-induced malaria, the course co-infection was followed 95 longitudinally and quantified in terms of parasitemia, changes in body mass, body 96 temperature, plasma lactate levels, brain histopathology and survival. To analyse the 97 influence of co-infection on the systemic cytokine response, plasma concentrations of 98 IFN-, TNF-, IL-5, IL-10, IL-13, IFN-inducible protein (IP-10), monocyte 99 chemoattractant protein-1 (MCP-1), monokine induced by IFN-(MIG) and 100
Multiplex analysis of plasma cytokine concentration 179
Mice with an 8-to-9-weeks-old S. mansoni infection were co-infected with P. 180 berghei and were analysed together with mono-infected and uninfected controls. 181
Plasma from four to seven mice per group and time point was obtained 3 days before 182 and 1, 4 and 6 days after infection with P. berghei. Blood was collected from the 183 orbital sinus of the mouse and plasma was prepared in plasma tubes (BD 184 Microtainer, Franklin Lakes, NJ, USA) according to the manufacturer's instructions. 
Lactate measurement and determination of RBC parameters 211
For lactate determination, plasma samples of seven S. mansoni-P. berghei-co-212 infected, seven P. berghei-mono-infected, four S. mansoni-mono-infected and seven 213 uninfected control mice were obtained between days 6 and 7 after infection with 214 P. berghei and were analysed by enzymatic methods using an ESAT 6661 215 (Eppendorf, Hamburg, Germany). 216
To measure RBC parameters on day 4 after infection with P. berghei, the 217 blood of six S. mansoni-P. berghei-co-infected, seven P. berghei-mono-infected, six 218 S. mansoni-mono-infected and four uninfected control mice was analysed using a 219 For the analysis of brain histopathology, the cerebral score with the ordinal 233 outcomes 0, 1 and 2 was described by an ordinal logistic regression model taking 234 into account the presence or absence of an infection by P. berghei ANKA and S. 235 mansoni. The interaction of the two factors was not significant, therefore the model 236 included only the two factors in an additive way. The observed outcomes are shown 237 in a mosaic plot (Fig. 6 ). The order of the four groups takes into account the 238 estimated parameters of the model. 239
To analyse body temperatures on day 5 after Plasmodium infection, data were 240
Box-Cox-transformed to stabilize variances and were compared using bi-factorial 241 ANOVA followed by Tukey's Honestly Significant Difference (HSD) test for 242 comparisons between the groups. 243
In order to compare parasitemia and body weight between the experimental 244 groups at different days after the infection, ANOVA was performed. For both 245 analyses, the model included the fixed factors "group" and "day" together with the 246 interaction of "group" and "day" and the random factor "animal" nested under the 247 factor "group". As parasitemias were originally expressed as percentages, they were 248 transformed via the logit transformation in order to achieve normally distributed data. 249
The estimation method for the model parameters was Restricted Maximum 250 Likelihood (REML). To quantify the effects, the means for the individual groups and 251 days were described together with their 95% confidence intervals. (Fig. 1) . Mean parasitemia in S. mansoni-P. 283
berghei-co-infected mice was still higher on days 5 and 6, but differences were no 284 longer significant. In those animals surviving the period of susceptibility to CM, a 285 decline in parasitemia could be observed around day 7, which was followed by a 286 rapid increase from day 8 onwards. 287
On day 0, percentages of reticulocytes were significantly increased 288 approximately two-fold in S. mansoni-mono-infected mice compared with uninfected 289 controls ( Fig. 2A) and numbers of RBCs were significantly reduced (P 0.002) (Fig.  290   2B ). Reticulocyte percentages in S. mansoni-mono-infected mice were inversely 291 correlated with erythrocyte counts (Fig. 2C) To investigate whether a pre-existing patent Schistosoma-infection influences 296 disease severity of P. berghei malaria, body mass and rectal temperatures were 297 determined. Body mass was measured continuously following injection of malaria 298 parasites. Data were analysed up to day 6, when the majority of the P. berghei-299 infected animals died with symptoms of severe disease. For comparisons between 300 the four experimental groups, significance levels after Bonferroni-Holm's P value 301 adjustment were P < 0.0033. On days 5 and 6, S. mansoni-P. berghei-co-infected 302 and P. berghei-mono-infected animals were significantly lighter than S. mansoni-303 mono-infected and uninfected control mice (P < 0.001) (Fig. 3A) . This weight loss 304 was more profound in the S. mansoni-P. berghei-co-infected group (P 0.003). 305
Interestingly, on day 2, S. mansoni-mono-infected mice tended to be lighter than P. 306 berghei-mono-infected mice (P = 0.026), and on day 5 they tended to be lighter than 307 uninfected controls (P = 0.039), indicating that the most severe weight loss in 308 S. mansoni-P. berghei-co-infected mice probably resulted from a combined effect of 309 the two parasites. While most of the uninfected controls had gained weight by day 6 310 (five out of seven mice), most of the S. mansoni-mono-infected mice had lost weight 311 (four out of five mice). Plasmodium berghei-mono-infected and S. mansoni-312 P. berghei-co-infected animals surviving day 8 also lost weight during the period of 313 susceptibility to cerebral malaria, but temporarily regained some weight around days 314 8 and 9 (Fig. 3B) . 315
Rectal temperatures were compared on day 5 after inoculation with P. berghei, 316 when all P. berghei-mono-infected and all S. mansoni-P. berghei-co-infected mice 317 were still alive. Plasmodium berghei-mono-infected and S. mansoni-P. berghei-co-318 infected mice had significantly lower body temperatures than S. mansoni-mono-319 infected and uninfected controls (P < 0.05) (Fig. 4) . There was no statistical 320 difference either between P. berghei-mono-infected and S. mansoni-P. berghei-co-321 infected mice or between S. mansoni-mono-infected and uninfected controls. 322 323
Pre-exisiting schistosomiasis does not influence survival after co-infection with 324

P. berghei ANKA 325
To establish whether a pre-existing patent S. mansoni-infection influences 326 survival during the period of susceptibility to CM, mice were monitored after day 0 in 327 relation to infection with P. berghei. Between days 6 and 8, the majority of the P. 328 berghei-infected animals either died overnight or developed symptoms of terminal 329 disease (clinical score value of 4) and were sacrificed. Concurrent patent 330 schistosomiasis did not alter the low survival rate, as only 11% of the S. mansoni-P. 331 berghei-co-infected animals (two out of 18) and 25% of the P. berghei-mono-infected 332 mice (four out of 16) survived the critical period (Fig. 5) . This difference in survival 333
was not significant (P = 0.28). In the S. mansoni-mono-infected group, one animal 334 died 67 days after exposure to cercariae. Necropsy revealed severe intestinal 335 inflammation and extensive bleeding, especially in the region of the caecum. In 336 contrast, the caecum and colon of the other S. mansoni-mono-infected and 337
S. mansoni-P. berghei-co-infected
mice either seemed intact or displayed diffuse 338 macrosocopic haemorrhages. 339 340
Brain histopathology is decreased in S. mansoni-P. berghei-co-infected mice 341
To assess the effect of patent schistosomiasis on P. berghei-induced brain 342 pathology, we analysed brain sections of P. berghei-mono-infected and S. mansoni-343 P. berghei-co-infected mice that had been sacrificed with symptoms of fatal disease 344 during the period of susceptibility to CM. Results are presented in form of a mosaic 345 plot (Fig. 6 ). Strikingly, in the S. mansoni-P. berghei-co-infected group no signs of 346 brain pathology (CSV 0) could be detected in 42% of the mice that had been killed 347 with symptoms of severe disease (Fig. 7A ). In 50% of the animals pathology was 348 moderate (CSV 1) and in 8% (n = 1) severe (CSV 2). In contrast, all P. berghei-349 mono-infected animals showed sequestration ( mansoni. In all mice that were killed with symptoms of severe disease, a mono-360 infection with P. berghei ANKA led to brain histopathology but the severity varied 361 amongst the animals. 362
Interestingly, none of the S. mansoni-P. berghei-co-infected mice with a CSV 363 of 0 showed any signs of neurological involement such as paralysis or convulsions. 364
As well as hypothermia, which was observed in all terminally-ill mice, they exhibited 365 signs of general prostration (hunching, inability to walk) and an abnormal breathing 366 pattern. In contrast, neurological signs were present in 56% of the P. berghei-mono-367 infected and S. mansoni-P. berghei-co-infected mice with a CSV of 1 and in 80% of 368 the P. berghei-mono-infected and S. mansoni-P. berghei-co-infected mice with a 369 CSV of 2. None of the animals that died between days 6 and 8 suffered from severe 370 anaemia, as judged by skin colour (pink ears and pink plantar surface and digits of 371 forelimbs). Moreover, on day 4 there were no significant differences in RBC counts, 372 haemoglobin concentrations (Hb), and haematocrit levels (HCT) between the four 373 experimental groups (median and interquartile range; S. involved in fatal outcomes during the period of susceptibility to CM, we investigated 388 whether P. berghei-infected mice developed lactic acidosis, one of the key features 389 of circulatory shock. We also compared parasitemias in mice that survived ('surviving 390 mice') and died ('dying mice') during the CM vulnerable period. 391
On days 6 to 8 after infection with P. berghei we observed no differences in 392 lactate concentrations between S. mansoni-P. berghei-co-infected, P. berghei-mono-393 infected, S. mansoni-mono-infected and uninfected control mice (Kruskal-Wallis test, 394 P = 0.17) (data not shown). To investigate whether fatal outcomes in the period of 395 suceptibility to CM were related to parasitemia, we compared the individual time 396 courses of parasitemia between dying and surviving mice. As there was no statistical 397 difference in survival between S. mansoni-P. berghei-co-infected and P. berghei-398 mono-infected mice, for these comparisons all P. berghei-infected mice were 399 grouped together. As can be seen in Fig. 8A , the majority of dying mice had 400 parasitemias above 6% on days 6 and 7 (27 out of 28 animals), whereas the majority 401 of surviving mice had parasitemias below 6% during this period (five out of six mice). 402
Body temperature was negatively correlated with parasitemia (P < 0.001) (Fig. 8B) . 403 404
Schistosoma mansoni-P. berghei-co-infected mice have higher plasma 405 concentrations of IL-5 and IL-13, and on day 6, lower plasma concentrations of IFN-406 , MCP-1 a, MIG and IL-10 than P. berghei-mono-infected mice 407
To assess the systemic immune response to co-infection, concentrations of 408 nine different cytokines were analysed in S. mansoni-P. berghei-co-infected, 409 
P. berghei-mono-infected, S. mansoni-mono-infected
berghei-co-infected and P. berghei-mono-infected animals that developed symptoms 498 of terminal disease in the acute phase of the infection. Strikingly, co-infection with 499
Schistosoma had a significant protective effect on brain pathology. However, the 500 protective effect of patent schistosomiasis was smaller than the harmful effect of 501 P. berghei-induced malaria. Moreover, cerebral pathology varied among P. berghei-502 mono-infected mice, suggesting that the down-modulatory effect of schistosomiasis 503 abrogated brain pathology in those malaria-infected mice that would otherwise have 504 developed 'mild' pathology, and diminished pathology in animals that were prone to 505 severe disease. instead attributed to immune-mediated metabolic disturbances (Piguet et al., 2002) . 552
It has also been proposed that early death during P. berghei malaria might 553 result from circulatory shock, a key feature of which is lactic acidosis (Chang et al., 554 2001). As no increase in lactate concentrations could be detected in any of our 555 P. berghei-infected mice that succumbed around day 6, it seems unlikely that lactic 556 acidosis played a role in the early death of P. berghei-mono-infected and S. mansoni-557 P. berghei-co-infected mice in the present experiments. As on day 4 there were no 558 significant differences in RBC parameters between the four experimental groups, this 559
indicates that P. berghei-mono-infected and S. mansoni-P. berghei-co-infected mice 560 did not die due to severe anaemia. However, our results suggest a causal link 561 between P. berghei-induced mortality and increased malaria parasite levels during 562 the CM vulnerable period. Moreover, inverse correlation of parasitemia with body 563 temperature provides additional evidence for a direct influence of parasitemia on the 564 pathogenesis of malarial disease. Thus, mice with low parasitemia were probably 565 protected due to insufficient antigenic stimulation by P. berghei parasites. 566
In contrast to our experiments, Waknine-Grinberg et al. (2010) berghei-mono-infected mice. In contrast, our C57BL/6 mice were infected with higher 577 numbers of P. berghei-infected RBCs (10 6 ) and the majority of P. berghei-mono-578 infected and S. mansoni-P. berghei-co-infected animals developed fatal disease on 579 day 6, a time point at which S. mansoni-P. berghei-co-infected C57BL/6 mice had 580 significantly lower plasma concentrations of IFN-and IL-10. Thus, it is possible that 581 the differences in the outcome of the two S. mansoni-P. berghei co-infection studies 582 are related to the differences in the P. berghei infection dose and/or the genetic 583 background of the host. 584
The disease outcome of P. berghei malaria could also vary with the stage of 585 the concomitant schistosome infection. In the present experiments, we applied 8-to-586 9-week-old S. mansoni infections, which are marked by strong Th2 responses and 587 are considered as acute stage infections. In contrast, schistosome infections at later 588 time points are characterized by an expansion of regulatory T cells and increased 589 activation of immunosuppressive networks (chronic infections) (Singh et al., 2005) . 590 Therefore, it might be interesting to study whether different P. berghei-related 591 disease patterns are found during chronic S. mansoni infections. 592
In conclusion, we have demonstrated that a concomitant 8-to-9-week-old 593 S. mansoni infection conferred protection against brain pathology but not against 594 severe disease and mortality in the C57BL/6 mouse model of CM. Fatal outcome 595 was instead associated with parasitemia. Taken S. mansoni-mono-infected (Sm; n = 4), and uninfected control mice (n = 7). Symbols indicate means and 95% confidence intervals. Data were Box-Cox-transformed and compared using bi-factorial analysis of variance followed by Tukey's Honestly Significant Difference (HSD) test. Asterisks indicate significant differences between the groups (*P < 0.05).
Fig. 5. Survival after co-infection with Schistosoma mansoni and
Plasmodium berghei. Schistosoma mansoni-P. berghei-co-infected C57BL/6 mice (Sm+PbA; n = 18) were examined together with P. berghei-mono-infected mice (PbA; n = 16). Data were analysed using a Wilcoxon test. After 6 to 8 days of infection with P. berghei, the majority of the malaria-infected animals died, and there was no difference in survival between S. mansoni-P. berghei-co-infected and P. bergheimono-infected animals (P = 0.28). Correlation was tested using the Spearman rank correlation (r 2 = -0.57; P < 0.001; n = 34). RBC, red blood cell. 
